This segment focuses on the research, development, and clinical evaluation of small molecule inhibitors targeting Fibroblast Growth Factor Receptors (FGFRs). The primary focus is on TYRA-300, a selective FGFR3 inhibitor, for the treatment of muscle invasive bladder cancer. Research and development activities include preclinical studies, clinical trials, and the optimization of drug candidates. Technologies employed include structure-based drug design using the SNAP platform, which enables rapid structural design through iterative molecular snapshots. The segment addresses unmet needs in oncology, specifically in cancers driven by FGFR alterations. The goal is to improve patient outcomes by overcoming tumor resistance. Market positioning involves targeting specific patient populations with high unmet needs. Future opportunities include expanding the pipeline to address other FGFR-related cancers and exploring combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships include collaborations with research institutions and patient advocacy groups.

The SNAP (Structural Nano-Assembly Platform) platform is a core technology segment at Tyra Biosciences. This platform is a rapid structure-based design process that enables the development of next-generation precision medicines. The SNAP platform utilizes iterative molecular snapshots to accelerate the drug discovery process. Research and development activities include the continuous improvement and refinement of the platform, as well as its application to identify and optimize drug candidates. The platform is used across multiple therapeutic areas, including oncology, with a focus on developing targeted therapies. The patient impact is realized through the faster identification and development of effective drug candidates. Market positioning is based on the platform's ability to accelerate drug discovery and improve the chances of success. Future opportunities include expanding the platform's capabilities and applying it to a wider range of disease targets. The platform is a key component of Tyra's competitive advantage, enabling the company to rapidly design and develop novel therapies.